Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors

Although the clinical development of immune checkpoint inhibitors (ICIs) therapy has ushered in a new era of anti-tumor therapy, with sustained responses and significant survival advantages observed in multiple tumors, most patients do not benefit. Therefore, more and more attention has been paid to the identification and development of predictive biomarkers for the response of ICIs, and more in-depth and comprehensive understanding has been continuously explored in recent years. Predictive markers of ICIs efficacy have been gradually explored from the expression of intermolecular interactions within tumor cells to the expression of various molecules and cells in tumor microenvironment, and been extended to…

• NN
  National Natural Science Foundation of China

  Awards: Grant 81672275 and 81874052, 81672275, 81874052
• PG
  People's Government of Jilin Province
• DO
  Department of Science and Technology of Jilin Province

  Awards: 20190303146SF, 20180101009JC, JJKH20190020KJ